Cargando…
The pharmacokinetics of valganciclovir prophylaxis in pediatric solid organ transplant patients at risk for Epstein–Barr virus disease
Antiviral prophylaxis with valganciclovir is used frequently in pediatric solid organ transplant patients to prevent Epstein–Barr virus (EBV)-induced infections and tissue-invasive disease including post-transplant lymphoproliferative disorder (PTLD). This approach is untested in clinical trials and...
Autores principales: | Vezina, Heather E, Brundage, Richard C, Nevins, Thomas E, Balfour, Henry H |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3262369/ https://www.ncbi.nlm.nih.gov/pubmed/22291482 |
Ejemplares similares
-
1564. Lower Rates of Epstein–Barr Virus (EBV) Viremia in Pediatric Solid Organ Transplant (SOT) Recipients Who Received Valganciclovir Prophylaxis
por: Moulton, Elizabeth A, et al.
Publicado: (2018) -
2715. Toxicities and clinical consequences of valganciclovir prophylaxis in solid organ transplant recipients
por: Lahoud, Chloe, et al.
Publicado: (2023) -
New algorithm for valganciclovir dosing in pediatric solid organ transplant recipients
por: Åsberg, A, et al.
Publicado: (2014) -
1702. Assessing the Safety and Efficacy of Valganciclovir Dosing for Cytomegalovirus Prophylaxis in Solid Organ Transplant Recipients on Hemodialysis
por: Yee, Jason, et al.
Publicado: (2020) -
Efficacy of Extended Valganciclovir Prophylaxis in Preventing Cytomegalovirus Infection in Pediatric Kidney Transplantation
por: Hashim, Faris, et al.
Publicado: (2014)